Mangoceuticals, Inc. is a biotechnology company focused on developing innovative wellness and lifestyle products that leverage the benefits of natural ingredients. The company specializes in formulating and marketing supplements aimed at enhancing men's health, vitality, and overall quality of life. By combining cutting-edge research with the power of nature, Mangoceuticals aims to provide consumers with effective and safe solutions for improving their well-being, all while promoting a healthier lifestyle. Through its commitment to quality and sustainability, the company seeks to establish itself as a leader in the health and wellness industry. Read More
Mangoceuticals (NASDAQ: MGRX) operating under the MangoRx and PeachesRx brands, announced initial success for its newly launched all-inclusive injectable testosterone replacement therapy program priced at $99 per month, which includes doctor visits, consultations, lab work and prescribed medication. Since launching in mid-December, month-over-month sales of the injectable TRT program have increased 336% while customer acquisition costs declined 54%, reflecting what the company described as growing demand for convenient hormone health solutions delivered through its telehealth platform. MangoRx expects TRT to serve as a primary growth driver, alongside oral formulations including PRIME by MangoRx powered by Kyzatrex, as it seeks to expand its presence in the global TRT market, estimated at approximately $2.1 billion to $2.2 billion in 2025.
Mangoceuticals (NASDAQ: MGRX) operating under the MangoRx and PeachesRx brands, announced initial success for its newly launched all-inclusive injectable testosterone replacement therapy program priced at $99 per month, which includes doctor visits, consultations, lab work and prescribed medication. Since launching in mid-December, month-over-month sales of the injectable TRT program have increased 336% while customer acquisition costs declined 54%, reflecting what the company described as growing demand for convenient hormone health solutions delivered through its telehealth platform. MangoRx expects TRT to serve as a primary growth driver, alongside oral formulations including PRIME by MangoRx powered by Kyzatrex, as it seeks to expand its presence in the global TRT market, estimated at approximately $2.1 billion to $2.2 billion in 2025.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Friday. Below you can find the top gainers and losers in today's session.
Mangoceuticals had also recently filed a trademark application for “MULTI-DAT” with the United States Patent and Trademark Office in a bid to expand into the digital asset space
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Friday. Let's explore the market movements and identify the stocks with significant gaps.
ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer in medical imaging and digital innovation, is redefining the intersection of healthcare technology and decentralized finance through its groundbreaking Thermo Acoustic Enhanced UltraSound (TAEUS®) platform and its newly launched Digital Asset Treasury (DAT) strategy. Together, these initiatives position ENDRA as one of the most forward-looking companies in both the medtech and blockchain arenas.
The regular session of the US market on Friday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
